ENDO: Teprotumumab Shows Long-Term Efficacy for Thyroid Eye Disease

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on June 11, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, June 11, 2024 -- Most patients with thyroid eye disease treated with teprotumumab do not require additional treatments nearly two years later, according to a study presented at the annual meeting of the Endocrine Society, held from June 1 to 4 in Boston, and simultaneously published online June 2 in Thyroid.

George J. Kahaly, M.D., Ph.D., from the Johannes Gutenberg University Medical Center in Mainz, Germany, and colleagues analyzed the long-term maintenance of responses with teprotumumab from previous trials. The analysis included 112 patients who received seven or eight infusions of teprotumumab in the phase 2, phase 3 (OPTIC study), and OPTIC Extension (OPTIC-X) studies.

The researchers found that at week 72, 52 of 57 patients were responders for clinical activity score (CAS ≥2-point improvement), 51 of 57 were responders for the European Group of Graves' Orbitopathy ophthalmic composite outcome, 35 of 48 were responders for diplopia (≥1 Gorman grade improvement), 38 of 56 were responders for proptosis (≥2-mm improvement), and 37 of 56 had an overall response (improvement in proptosis plus CAS). The mean reduction in proptosis was 2.68 mm, while disease inactivation (CAS ≤1) was detected in 40 of 57 participants. Mean Graves' Ophthalmopathy quality-of-life score improvement was 15.22. At 99 weeks, 17.9 percent of patients reported additional thyroid eye disease therapy during formal and extended follow-up.

"As physicians consider treatment approaches for their thyroid eye disease patients, they now have longer-term data to support the use of teprotumumab in appropriate patients," Kahaly said in a statement.

The study was sponsored by Amgen, the manufacturer of teprotumumab.

Abstract/Full Text

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-06-12 03:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords